Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$31.49 USD
-0.18 (-0.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $31.48 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 281 - 295 ( 295 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Focus Now on the Upcoming EHA Data Deluge
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
IDH Programs Positioned to be the Next Standard-of-Care in IDHm-AML
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Introduction of AG-881 Throws a Curveball,Reiterate Neutral
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Healthcare -Biotechnology: Catalyst Tracker Through Mid-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Healthcare: Biotechnology: Its Yogi Berra All Over Again
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Lull in News Flow Till 2H15, Awaiting Better Entry Points
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
4Q/FY-14 Preview, Upcoming AG-120 Data Key to Support Valuation
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Transformational Science, But Valuation Keeps Us On the Sidelines
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D